Table 2 Baseline characteristics of the 59 studies included in the meta-analysis
No. | Study | Area | Sample size | Follow-up period (years) | Referring to H. pylori a | Mean age (years) | Male (%) | TNM stage | H. pylori-positive rate (%) | Samples for H. pylori detection | Statistical analysis | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Gong, 2020 [22] | China | 200 | 3.00 | Y | 32.2 | 61.0 | I-II | 78.0 | Tissue | U | 6 |
2 | Kim, 2020 [23] | Korea | 1143 | 15.00 | N | 60.1 | 67.6 | I-IV | 85.10 | Tissue and serum | M | 9 |
3 | Tsao, 2020 [24] | America | 176 | 15.00 | Y | 69 | NA | I-III | 24.53 | Tissue | M | 8 |
4 | Xu, 2020 [25] | China | 319 | 10.00 | Y | 26–84 | 68.7 | I-IV | 80.56 | Tissue | M | 9 |
5 | Zhao, 2020 [26] | China | 110 | 6.67 | N | NA | 76.4 | IV | 35.45 | NA | U | 7 |
6 | Taiwan | 356 | 5.00 | Y | NA | 69.7 | I-III | 52.00 | Tissue | M | 8 | |
7 | He, 2019 [28] | China | 460 | 5.00 | Y | 64 | 73.5 | I-IV | 54.6 | Serum | U | 7 |
8 | Morgan, 2019 [13] | America | 249 | 10.00 | Y | 65 | 61.8 | I-IV | NA | NA | M | 7 |
9 | Shimoda, 2019 [29] | Japan | 52 | 7.67 | N | NA | 67.3 | I-IV | 88.00 | Tissue | U | 8 |
10 | Japan | 214 | 8.33 | N | 66 | 68.2 | I-IV | 86.4 | Tissue | M | 8 | |
11 | Wang, 2019 [32] | China | 956 | 5.00 | N | NA | 69.8 | I-III | 70.6 | Serum | U | 6 |
12 | Xu, 2019 [33] | China | 128 | NA | N | 59.3 | 69.5 | I-IV | NA | NA | U | 6 |
13 | Xue, 2019 [34] | China | 102 | 6.67 | N | NA | 57.8 | I-III | 54.9 | NA | U | 7 |
14 | Liu, 2018 [35] | China | 99 | 5.00 | Y | 59.5 | 61.6 | NA | 70.7 | Tissue | U | 8 |
15 | Martinson, 2018 [36] | America | 52 | 8.83 | Y | 59.8 | 62.1 | I-IV | 41.3 | NA | U | 7 |
16 | Nishizuka, 2018 [37] | Japan | 491 | 5.23 | Y | NA | 67.0 | I-III | 35.6 | Tissue | U | 8 |
17 | Park, 2018 [38] | Korea | 244 | 10.00 | N | 53.8 | 46.2 | NA | 49.1 | NA | U | 7 |
18 | Peng, 2018 [39] | China | 333 | 6.00 | N | 59.4 | 53.8 | I-III | 37.2 | Medical record | M | 7 |
19 | Xu, 2018 [40] | China | 280 | 7.50 | N | NA | 61.4 | I-IV | 82.5 | Medical record | U | 7 |
20 | Jung, 2017 [6] | Korea | 314 | 17.33 | Y | 55.4 | 66.9 | I-III | 40.8 | Tissue | M | 9 |
21 | Lai, 2017 [8] | China | 98 | 5.00 | N | 57.0 | 52.0 | I-IV | 51.0 | Medical record | M | 8 |
22 | Lv, 2017 [41] | China | 353 | 7.50 | Y | NA | 71.1 | I-IV | 53.5 | Serum | U | 6 |
23 | Nogueira, 2017 [42] | Portugal | 82 | 3.00 | Y | 66.6 | 54.9 | I-IV | 62.2 | Tissue and serum | U | 7 |
24 | Tsai, 2017 [43] | Taiwan | 1010 | 12.00 | N | 63.7 | 59.6 | I-III | 19.6 | Medical record | U | 7 |
25 | Tsai, 2017 [44] | Taiwan | 567 | 10.00 | Y | 62.2 | 61.4 | I-IV | 76.7 | Tissue or serum | M | 9 |
26 | Xiao, 2017 [45] | China | 469 | 17.00 | N | 58.9 | 72.3 | I-III | 8.96 | NA | M | 8 |
27 | Chen, 2016 [46] | Taiwan | 67 | 5.00 | Y | 68.5 | 70.1 | I-IV | 65.7 | NA | U | 6 |
28 | Kim, 2016 [47] | Korea | 167 | 11.30 | Y | 57.0 | 69.2 | I-IV | 50.9 | Tissue | M | 9 |
29 | Liu, 2016 [48] | China | 153 | 7.92 | Y | 60.0 | 71.8 | I-IV | 70.0 | Medical record | M | 8 |
30 | Liu, 2016 [49] | China | 268 | 8.00 | N | NA | NA | I-IV | NA | NA | M | 7 |
31 | Postlewait, 2016 [50] | America | 559 | 4.15 | Y | 64.6 | 56.0 | I-III | 18.6 | NA | M | 8 |
32 | Xu, 2016 [19] | China | 1412 | 5.00 | N | 64.0 | 68.6 | I-III | 78.8 | NA | U | 7 |
33 | Zhao, 2016 [12] | China | 600 | 10.00 | Y | 60.0 | 71.3 | I-IV | 79.2 | Medical record | M | 8 |
34 | Zhou, 2016 [51] | China | 152 | 10.00 | Y | 33.6 | 34.9 | I-IV | 51.1 | Tissue | U | 8 |
35 | Bautista, 2015 [52] | America | 802 | 5.00 | Y | 66.0 | 58.0 | I-IV | 74.1 | Medical record | M | 8 |
36 | García-González, 2015 [53] | Spain | 558 | 10.33 | Y | 69.8 | 68.7 | I-IV | 68.3 | Tissue | M | 9 |
37 | Shen, 2015 [54] | Hong Kong | 126 | NA | Y | 61.1 | 69.3 | I-IV | 41.3 | NA | U | 7 |
38 | Wang, 2015 [55] | China | 82 | 2.50 | Y | 63.3 | NA | I-IV | 54.0 | Tissue | U | 7 |
39 | Wei, 2015 [56] | China | 166 | 5.00 | Y | 62.3 | 65.1 | I-IV | 73.5 | Medical record | M | 8 |
40 | Zhang, 2015 [57] | China | 65 | 3.33 | Y | 66.7 | 67.7 | I-II | 55.4 | Serum | M | 8 |
41 | Fang, 2014 [58] | China | 252 | 6.50 | Y | NA | 55.9 | NA | 84.5 | NA | M | 7 |
42 | Gong, 2014 [59] | Korea | 308 | 9.35 | Y | 63.6 | 70.9 | I-IV | 84.1 | Serum | U | 8 |
43 | Jiang, 2014 [18] | China | 377 | 8.58 | N | 64.0 | 67.1 | I-III | 45.9 | NA | M | 8 |
44 | Posteraro, 2014 [9] | Italy | 110 | 10.00 | Y | 67.3 | 54.0 | I-IV | 78.0 | Tissue | U | 8 |
45 | Pryczynicz, 2014 [17] | Poland | 71 | 7.00 | N | NA | 69.0 | I-IV | 52.1 | Tissue | U | 8 |
46 | Roberts, 2014 [10] | Jamaica | 77 | 10.92 | Y | 67.0 | 45.6 | NA | 19.5 | NA | U | 7 |
47 | Suzuki, 2014 [60] | Japan | 381 | 10.00 | N | 67.1 | 72.9 | I-IV | 91.3 | NA | M | 9 |
48 | Li, 2013 [11] | China | 156 | 5.99 | Y | 56.0 | 72.8 | I-IV | 46.3 | Tissue | M | 8 |
49 | Wang, 2013 [61] | China | 261 | 4.92 | Y | 61.0 | 77.0 | I-IV | 72.0 | Tissue | M | 9 |
50 | Choi, 2012 [62] | Korea | 61 | 5.00 | Y | 57.0 | 57.4 | NA | 31.1 | Medical record | U | 7 |
51 | Hur, 2012 [63] | Korea | 174 | 3.33 | Y | NA | 37.9 | I-IV | 63.8 | Tissue and serum | U | 8 |
52 | Kang, 2012 [64] | Korea | 274 | 15.33 | Y | 54.0 | 69.0 | I-IV | 61.0 | Tissue | M | 9 |
53 | Syrios, 2012 [65] | Greece | 218 | 5.42 | Y | 59.0 | 67.4 | I-IV | 34.9 | Serum | U | 6 |
54 | Santos, 2011 [66] | Brazil | 68 | 17.28 | Y | 59.4 | 51.5 | I-IV | 50.0 | Tissue | U | 7 |
55 | Qiu, 2010 [67] | China | 157 | 6.82 | Y | 57.2 | 68.2 | I-IV | 31.2 | Tissue | U | 6 |
56 | Marrelli, 2009 [68] | Italy | 220 | 18.33 | Y | 68.0 | 58.0 | I-IV | 89.1 | Tissue or serum | M | 9 |
57 | Chen, 2006 [69] | Taiwan | 79 | 4.00 | Y | 63.3 | 68.4 | I-III | 38.0 | Medical record | M | 7 |
58 | Meimarakis, 2006 [70] | Germany | 166 | 12.17 | Y | 65.0 | 60.2 | I-IV | 75.3 | Tissue or serum | M | 9 |
59 | Lee, 1995 [5] | Taiwan | 128 | 5.00 | Y | 59.0 | 57.0 | I-IV | 64.0 | Serum | U | 8 |